What does Pharmala Biotech Holdings Inc. do?

Pharmala Biotech Holdings Inc. (MDMA.CN) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is MDMA.CN's market cap?

Pharmala Biotech Holdings Inc. (MDMA.CN) has a market capitalization of approximately $26.8 million, as of August 28, 2026, based on the most recent share price and shares outstanding.

Does MDMA.CN pay a dividend?

No — Pharmala Biotech Holdings Inc. (MDMA.CN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is MDMA.CN profitable?

Pharmala Biotech Holdings Inc. (MDMA.CN) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

MDMA.CN

Pharmala Biotech Holdings Inc.

CNQ·Biotechnology · Healthcare

C$0.25C$0.01+2.08%

Market capC$26.76M·Aug 28 1:33 PM UTC

Price Chart

C$0.25+C$0.01 (+2.08%)today

+206.25%CAGR +27.37%

Select date range

FromTo

Jan 11, 2022Jan 11, 2022 → Aug 28, 2026· 4.6 yrsAug 28, 2026

Key Metrics

MDMA.CN does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings DateFeb 28

Last Report DateNov 30

Reported vs EstimateC$0.00

Earnings Surprise—

FinancialsFinancials Tab

RevenueC$1.27M

Net Income−C$1.61M

Net Margin−126.9%

Operating Cash Flow−C$968.53K

Capital ExpendituresC$36.14K

Free Cash Flow−C$993.75K

Return on Equity−83.3%

Return on Invested Capital−22.9%

Net CashC$245.06K

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for MDMA.CN and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how MDMA.CN's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MDMA.CN and 80,000+ other tickers.

About Pharmala Biotech Holdings Inc.

Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.

CEO: Nicholas Kadysh
Sector: Healthcare
Industry: Biotechnology
Exchange: CNQ
Employees: 5
Website: pharmala.ca

Peers

Peers Tab

MRVL.V

Marvel Biosciences Corp.

Cap

C$9.5M

PHRM.CN

PharmaTher Holdings Ltd.

Cap

C$5.5M

BETR.CN

BetterLife Pharma Inc.

Cap

C$46.9M

Latest News

News Tab

No recent news available.

Frequently Asked Questions About MDMA.CN

What does Pharmala Biotech Holdings Inc. do?: Pharmala Biotech Holdings Inc. (MDMA.CN) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is MDMA.CN's market cap?: Pharmala Biotech Holdings Inc. (MDMA.CN) has a market capitalization of approximately $26.8 million, as of August 28, 2026, based on the most recent share price and shares outstanding.
Does MDMA.CN pay a dividend?: No — Pharmala Biotech Holdings Inc. (MDMA.CN) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is MDMA.CN profitable?: Pharmala Biotech Holdings Inc. (MDMA.CN) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.